Description
The Highly Galactosylated Anti-CD79B (Polatuzumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Chronic lymphocytic leukemia (CLL)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD79B antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD79B
Full Name
CD79b Molecule
Background
CD79B (CD79b Molecule) is a Protein Coding gene.
Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia, Non-Bruton Type.
Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Innate Immune System.
Gene Ontology (GO) annotations related to this gene include transmembrane signaling receptor activity.
Alternative Names
CD79B; CD79b molecule, immunoglobulin-associated beta; CD79B antigen (immunoglobulin associated beta), IGB; B-cell antigen receptor complex-associated protein beta chain; B29; Ig-beta;
Gene ID
974
UniProt ID
P40259
Cellular Localization
Plasma membrane
Genecards
1699
Involvement in Disease
Its related pathways are B cell receptor signaling pathway (KEGG) and Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
Related Pathways
Cooperating with CD79A to initiate the signal transduction cascade activated by the b-cell antigen receptor complex (BCR), which leads to the internalization of the complex, transport to the late endosomes and antigen presentation. Enhancing the phosphorylation of CD79A may be by recruiting kinases that phosphorylate CD79A or by recruiting proteins that bind to CD79A and protect it from dephosphorylation.
Field of research
Phosphorylated on tyrosine upon B-cell activation by SRC-type Tyr-kinases such as BLK, LYN and SYK.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Polatuzumab
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human CD79B.
Antibody Indication
Chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia (CLL)
